Global Development Lead (GDL) , Clinical Development – Lung Cancer at Revolution Medicines

You're a seasoned oncology drug-development leader, ideally an MD with board certification in Medical Oncology or Hematology/Oncology and recognized expertise i

Work type: hybrid

Location: Redwood City, California, United States

Salary: $369,000 – $424,000/yr

Type: Full-time

Summary

You're a seasoned oncology drug-development leader, ideally an MD with board certification in Medical Oncology or Hematology/Oncology and recognized expertise in NSCLC, with at least 13 years of relevant experience. Revolution Medicines, a late-stage clinical oncology company, is offering this full-time, hybrid leadership role in Redwood City, California, with a base salary between $369,000 and $424,000 annually. * MD with board certification in Medical Oncology or Hematology/Oncology; adult solid tumor focus strongly preferred. * Recognized expertise in NSCLC. * Proven experience leading global, late-stage development programs, including pivotal Phase 2/3 studies. * Direct involvement in multiple global health authority interactions and regulatory submissions (NDA/BLA/MAA).

Job Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

We are seeking an experienced oncology drug-development leader to serve as Global Development Lead (GDL) for one of Revolution Medicines’ most advanced clinical programs. This is a senior, program-accountable leadership role with end-to-end ownership of clinical development strategy and execution for a late-stage asset, including pivotal studies, regulatory engagement, and long-range planning.

The GDL functions as the single point of clinical accountability for the assigned program, setting direction, driving alignment across functions, and representing the program at internal governance bodies and externally with investigators, key opinion leaders, and global health authorities. This position sits at the Executive Director level within Clinical Development and carries program-level accountability and authority typically associated with the most senior clinical leaders in the organization.

In addition to program ownership, the GDL serves as a senior clinical advisor to development leadership, contributing perspective to cross-program and enterprise-level development discussions as appropriate.

Responsibilities

Program & Clinical Strategy

• Own and lead the global clinical development strategy for the assigned program, integrating scientific, clinical, regulatory, biomarker, and commercial considerations.

• Partner closely with the Project Team Leader (PTL) or Lifecycle Team Leader (LCL) to ensure that clinical development strategy, positions and decision-making are fully represented and integrated within lifecycle planning and decision-making for the molecule, with clear alignment on roles, decision rights and accountability.

• Develop and maintain the Target Product Profile (TPP), Clinical Development Plan (CDP), risk assessments, scenario analyses, and long-range program roadmap.

• Present strategic recommendations to internal governance bodies (e.g., DRG, SMT, PRG, ePRG) and drive high-quality, timely program decision-making.

• Ensure strategy reflects deep disease-area insight, emerging science, competitive intelligence, and evolving regulatory expectations.

• Accountable for the design, execution, and delivery of pivotal and registration-enabling studies (Phase 2/3), including protocol strategy, enrollment and geographic planning, patient safety oversight, and data interpretation.

• Ensure alignment and harmonization across related studies within the program and across regions to support coherent regulatory and lifecycle objectives.

• Provide senior clinical leadership across functions to anticipate risk, resolve complex issues, and ensure delivery of critical milestones, leveraging matrixed teams rather than direct operational control.

• Guide preparation of regulatory briefing materials and serve as the senior clinical representative in global health authority interactions.

• Serve as the program’s senior medical authority, providing deep expertise in pancreatic and colorectal cancers.

• Translate scientific, translational, and biomarker insights into actionable clinical strategy.

• Engage key opinion leaders, investigators, advisory boards, and external experts to refine development strategy and strengthen scientific and clinical positioning.

• Serve as the clinical and strategic leader for the assigned program, with clear accountability for clinical direction and integrated decision-making across functions.

• Lead a high-performing, cross-functional Global Development Team, in close partnership with the PTL or LCL, ensuring clarity of direction, strong collaboration, and accountability for outcomes.

• Demonstrate the ability to lead through both influence and authority in situations where program priorities cut across functions, senior leaders, and organizational boundaries.

• Partner with Medical Affairs and Commercial colleagues to ensure alignment between clinical strategy and future market needs.

• Act as a visible senior leader within Clinical Development, modeling enterprise mindset and contributing to broader discussions on development strategy, standards, and best practices beyond the assigned program.

• Assume leadership of an established, multidisciplinary Clinical Development Team, including multiple senior direct reports, with immediate accountability for alignment, performance, and delivery across the program.

• Rapidly assess team capabilities, clarify roles and decision rights, and establish operating cadence to ensure seamless execution during critical late-stage development phases.

• Demonstrated ability to step into complex, high-visibility leadership situations and effectively lead teams through transition, inflection points, or accelerated timelines.

• Mentor senior clinical development staff and contribute to capability-building across the broader organization.

• Model Revolution Medicines’ values of scientific rigor, transparency, inclusiveness, and commitment to patients.

• Contribute to the evolution of development processes, tools, and governance practices that enhance efficiency, quality, and scalability across the portfolio.

• MD (or international equivalent) with board certification in Medical Oncology or Hematology/Oncology; adult solid tumor focus strongly preferred.

• Recognized expertise in NSCLC developed through academic clinical leadership and/or substantial industry experience.

• Depth of experience typically gained at least 13 years in oncology clinical development, or a combination of senior academic clinical leadership and relevant industry roles.

• (Academic leadership may be counted when directly related to oncology trials and patient care.)

• Demonstrated leadership of global, late-stage development programs, including design and execution of pivotal Phase 2/3 studies.

• Experience owning or leading global regulatory strategy, including direct involvement in multiple interactions with global health authorities.

• Experience contributing to or leading regulatory submissions (NDA/BLA/MAA); multiple submissions strongly preferred.

• Proven ability to align and influence senior stakeholders across a highly matrixed organization.

• Exceptional ability to communicate complex scientific and clinical concepts clearly to executives, cross-functional partners, and external experts.

• Demonstrated skill in navigating conflict, establishing role clarity, and building durable cross-functional trust.

• Demonstrated commitment to developing people and building strong, resilient teams.

• Excellent written and verbal communication skills.

• Ability to travel approximately 25–30% (domestic and international).

• San Francisco Bay Area preferred, but hybrid acceptable.

• Prior academic appointment in medical oncology with leadership of clinical trials.

• Experience integrating translational and biomarker strategies into late-stage clinical development.

• Publication record supporting disease-area credibility.

• Experience supporting commercialization planning or launch readiness.

• Exposure to cross-program or portfolio-level development strategy and governance.

The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.

Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

View this job on nocollar jobs